Skip to main content

Advertisement

SpringerLink
Log in

Adherence to anti-Parkinson drug therapy in the “REASON” sample of Italian patients with Parkinson’s disease: the linguistic validation of the Italian version of the “Morisky Medical Adherence scale-8 items”

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Information about patients’ adherence to therapy represents a primary issue in Parkinson’s disease (PD) management. To perform the linguistic validation of the Italian version of the self-rated 8-Item Morisky Medical Adherence Scale (MMAS-8) and to describe in a sample of Italian patients affected by PD the adherence to anti-Parkinson drug therapy and the association between adherence and some socio-demographic and clinical features. MMAS-8 was translated into Italian language by two independent Italian mother-tongue translators. The consensus version was then back-translated by an English mother-tongue translator. This translation process was followed by a consensus meeting between the authors of translation and investigators and then by two comprehension tests. The translated version of the MMAS-8 scale was then administered at the baseline visit of the “REASON” study (Italian Study on the Therapy Management in Parkinson’s disease: Motor, Non-Motor, Adherence and Quality Of Life Factors) in a large sample of PD patients. The final version of the MMAS-8 was easily understood. Mean ± SD MMAS-8 score was 6.1 ± 1.2. There were no differences in adherence to therapy in relationship to disease severity, gender, educational level or decision to change therapy. The Italian version of MMAS-8, the key tool of the REASON study to assess the adherence to therapy, has shown to be understandable to patients with PD. Patients enrolled in the REASON study showed medium therapy adherence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

APD:

Anti-Parkinson drug

HY:

Hoehn and Yahr

MMAS-4:

4-Item Morisky Medical Adherence Scale

MMAS-8:

8-Item Morisky Medical Adherence Scale

PD:

Parkinson’s disease

References

  1. Leopold NA, Polansky M, Hurka MR (2004) Drug adherence in Parkinson’s disease. Mov Disord 19:513–517

    Article  PubMed  Google Scholar 

  2. Grosset D, European PD therapy compliance study group (2010) Therapy adherence issues in Parkinson’s disease. J Neurol Sci 289(1-2):115–118

    Article  PubMed  Google Scholar 

  3. Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K et al (2009) Adherence to antiparkinson medication in a multicenter European study. Mov Disord 24:826–832

    Article  PubMed  Google Scholar 

  4. Valldeoriola F, Coronell C, Pont C, Buongiorno MT, Camara A, Gaig C, Compta Y, ADHESON Study Group (2011) Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson’s disease: the ADHESON study. Eur J Neurol 18:980–987

    Article  PubMed  CAS  Google Scholar 

  5. Tarrants ML, Denarié MF, Castelli-Haley J, Millard J, Zhang D (2010) Drug therapies for Parkinson’s disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother 8:374–383

    Article  PubMed  CAS  Google Scholar 

  6. Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA (2008) Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson’s disease. Mov Disord 23:359–365

    Article  PubMed  Google Scholar 

  7. Morisky DE, Malotte CK, Choi P et al (1990) A patient education program to improve adherence rate with antituberculosis drug regimens. Health Educ Q 17:253–268

    Article  PubMed  CAS  Google Scholar 

  8. Morisky DE, DiMatteo MR (2011) Improving the measurement of self-reported medication nonadherence: final response. J Clin Epidemiol 64:258–263

    Article  Google Scholar 

  9. Elm JJ, Kamp C, Tilley BC, Guimaraes P, Fraser D, Deppen P, Brocht A, Weaver C, Bennett S, NINDS NET-PD Investigators and Coordinators (2007) Self-reported adherence versus pill count in Parkinson’s disease: the NET-PD experience. Mov Disord 22:822–827

    Article  PubMed  Google Scholar 

  10. Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 10(5):348–354

    Article  Google Scholar 

  11. Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67–74

    Article  PubMed  CAS  Google Scholar 

  12. Acquadro C, Joyce CRB, Patrick DL, Ware JE, Wu AW, Scientific Advisory Committee (2004) Linguistic validation manual for patient-reported outcomes (PRO) instruments. MAPI Research Institute

  13. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56(1):33–39

    Article  PubMed  CAS  Google Scholar 

  14. Tinazzi M, Abbruzzese G, Antonini A, Ceravolo R, Fabbrini G, Lessi P, Barone P Reasons driving to treatment modifications in Parkinson’s disease: the cross-sectional phase of the REASON study (submitted)

  15. McDowell I, Newell C (1996) Measuring health: a guide to rating scales and questionnaires. Oxford University Press, New York

    Google Scholar 

  16. Measso GF, Cavarzeran F, Zappalà G et al (1993) The mini-mental state examination: normative study of a random sample of Italian population. Dev Neuropsychol 9:77–85

    Article  Google Scholar 

  17. Magni E, Binetti G, Bianchetti A, Rozzini R et al (1996) Mini-mental state examination: a normative study in Italian elderly population. Eur J Neurol 3:1–5

    Article  Google Scholar 

  18. Korb-Savoldelli V, Gillaizeau F, Pouchot J, Lenain E, Postel-Vinay N, Plouin PF, Durieux P, Sabatier B (2012) Validation of a French version of the 8-item Morisky medication adherence scale in hypertensive adults. J Clin Hypertens (Greenwich) 14:429–434

    Article  Google Scholar 

  19. Bailey GR, Barner JC, Weems JK, Leckbee G, Solis R, Montemayor D, Pope ND (2012) Assessing barriers to medication adherence in underserved patients with diabetes in Texas. Diabetes Educ 38:271–279

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and were fully responsible for all aspects of manuscript development. We are grateful to MediData (Modena, Italy) for data collection and statistical analysis. This research was sponsored by a grant from Boehringer-Ingelheim.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Sapienza University of Rome and IRCCS Neuromed Institute, Pozzilli (IS), Italy

    G. Fabbrini

  2. Neurosciences, Ophthalmology and Genetics Department, University of Genova, Genoa, Italy

    G. Abbruzzese

  3. Schola Medica Salernitana, University of Salerno, Salerno, Italy

    P. Barone

  4. Department for Parkinson’s Disease, IRCCS San Camillo, Venice, Italy

    A. Antonini

  5. Department of Neurological, Neuropsychological, Morphological and Movement Sciences, University of Verona, Verona, Italy

    M. Tinazzi

  6. Medidata, Studi e Ricerche, Modena, Italy

    G. Castegnaro & S. Rizzoli

  7. Department of Community Health Sciences, UCLA Fielding School of Public Health, Los Angeles, CA, USA

    D. E. Morisky

  8. Boehringer-Ingelheim Italia S.p.A, Medical Clinical Operation, Milan, Italy

    P. Lessi

  9. Neurosciences Department, University of Pisa, Pisa, Italy

    R. Ceravolo

Authors
  1. G. Fabbrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Abbruzzese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Barone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Antonini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Tinazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Castegnaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Rizzoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. E. Morisky
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Lessi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R. Ceravolo
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the REASON study group

Corresponding author

Correspondence to R. Ceravolo.

Additional information

The members of the REASON study group are listed in “Appendix”.

Appendix: The REASON study group

Appendix: The REASON study group

Steering committee:

  • Giovanni Abbruzzese, Dipartimento di Neuroscienze, Oftalmologia e Genetica—Università di Genova, Italy.

  • Angelo Antonini, Department for Parkinson’s Disease, IRCCS San Camillo, Venice, Italy.

  • Paolo Barone, Scuola Medica Salernitana, Università degli Studi di Salerno, Salerno, Italy.

  • Roberto Ceravolo, Dipartimento di Neuroscienze Azienda Ospedaliero-Universitaria Pisana, Italy.

  • Giovanni Fabbrini, Sapienza Università di Roma, and Neuromed Institute, Pozzilli (IS), Italy.

  • Michele Tinazzi, Dipartimento di Scienze Neurologiche, Neuropsicologiche, Morfologiche e Motorie, Università di Verona, Italy.

Participating centres:

  • M. A. B. Melone, C. Schettino, F. Califano, Az. Osp. Univ. Seconda Universtà di Napoli (Napoli).

  • M.G. Ceravolo, M. Capecci, E. Andrenelli, Az. Ospedali Riuniti (Ancona);

  • F. Iemolo, D. Spadaro, A. Carnemolla, Ospedale Civile R. Guzzardi (Vittoria);

  • F. E. Pontieri, C. Pellicano, D. Benincasa, Az. Osp. Sant’Andrea (Roma);

  • G. Fabbrini, S. Pietracupa, A. Latorre, Sapienza Università di Roma (Roma);

  • G. Tedeschi, A. Tessitore, A. Giordano, Seconda Università Federico II (Napoli);

  • U. Bonuccelli, D. Frosini, F. Vanelli, Ospedale Santa Chiara (Pisa);

  • G. Comi, M. A. Volonté, F. Spagnolo, Fondazione Centro San Raffaele (Milano);

  • A. Scaglioni, G. Abrignani, Ospedale di Vaio (Fidenza);

  • G. Abbruzzese, L. Avanzino, T. Tamburini, Università degli Studi di Genova (Genova);

  • A. Antonini, S. Facchini, R. Biundo, Ospedale San Camillo (Venezia Lido);

  • M. C. Altavista, C. Roberti, Ospedale San Filippo Neri (Roma);

  • G. Asteggiano, M. R. L’Episcopo, E. Saracco, Ospedale San Lazzaro (Alba);

  • T. Avarello, Az. Osp. Riuniti Villa Sofia-Cervello (Palermo);

  • G. Bono, G. Riboldazzi, S. Leva, Ospedale di Circolo e Fondazione Macchi (Varese);

  • M. Del Sette, E. Carabelli, E. Traverso, Ospedale Sant’ Andrea (La Spezia);

  • R. Michelucci, S. Nassetti, E. Pasini, Ospedale Bellaria (Bologna);

  • A. Padovani, E. Cottini, B. Bigni, Az. Osp. Spedali Civili (Brescia);

  • S. Ruggieri, N. Modugno, M. Fischetti, Istituto Mediterraneo Neuromed (Pozzilli);

  • A. Stefani, M. Pierantozzi, M. Stampanoni Bassi, Policlinico Tor Vergata (Roma);

  • M. Tinazzi, S. Ottaviani, D. Ajena, Ospedale Civile Maggiore—Borgo Trento (Verona);

  • G. Trianni, F. My, M. Caggiula, Ospedale Vito Fazzi (Lecce);

  • G. Valenti, S. Grioli, I. La Farina, Ospedale Garibaldi (Catania);

  • S. Zambito Marsala, C. Marchini, M. Gioulis, Ospedale San Martino (Belluno);

  • P. Barone, M. Picillo, M. Moccia, Università Federico II Napoli (Napoli);

  • A. Denaro, L. Sebastianelli, Istituto Chirurgico Ortopedico Traumatologico (Latina);

  • M. Onofrj, A. Thomas, Fondazione Università Gabriele D’Annunzio (Chieti);

  • C. Marini, F. De Santis, V. Spagnoli, Ospedale di Avezzano (Avezzano);

  • R. L’Erario, P. Passadore, Ospedale S. Maria della Misericordia (Rovigo);

  • E. Belgrado, M. Mucchiut, Az. Osp. Univ. S.Maria della Misericordia (Udine);

  • A. Priori, F. Cogiamanian, Fondazione Ospedale Maggiore Policlinico (Milano);

  • A. Marchet, Ospedale Martini (Torino).

Sponsorship:

  • Patrizia Lessi, Boehringer-Ingelheim, Milano, Italy.

Project Management, Statistical Analyses and data management:

  • MediData Studi e Ricerche, Modena: G. Castegnaro, A. Ori, S. Pirondi, S. Rizzoli, B. Roncari, S. Sala, S. Sgarbi, L. Simoni, F. Trevisan, L. Zanoli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fabbrini, G., Abbruzzese, G., Barone, P. et al. Adherence to anti-Parkinson drug therapy in the “REASON” sample of Italian patients with Parkinson’s disease: the linguistic validation of the Italian version of the “Morisky Medical Adherence scale-8 items”. Neurol Sci 34, 2015–2022 (2013). https://doi.org/10.1007/s10072-013-1438-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-013-1438-1

Keywords

Search

Navigation